For example, administration of an IFN-γ-/or IL-2-fused high-affinity anti-PD-L1 nanobody to mice bearing pancreatic tumors showed a phenotype shift in intratumoral macrophages toward M1-macrophage with approximately 50% reduction of tumor burden as well as enhanced infiltration of CD8+ T cells into TME (142). This evidence concerns the gene IL2 and neoplasm.